The CD95 (APO-1/Fas) death system in tumor progression

Number of publications: 9
Israeli Partner: G. Berke, Weizmann Institute of Science
German Partner: P. Krammer, DKFZ


Behrens, C. K., Igney, F. H., Arnold, B., Moller, P., Krammer, P. H.

CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice 166 (5), J Immunol, 3240-7, 2001

Berke, G., Krutovskikh, V., Yamasaki, H.

Connexin 37 gene is not mutated in lung carcinomas 3LL and CMT 195 (1), Cancer Lett, 67-72, 2003

Igney, F. H., Behrens, C. K., Krammer, P. H.

The influence of CD95L expression on tumor rejection in mice 33 (10), Eur J Immunol, 2811-21, 2003

Igney, F. H., Behrens, C. K., Krammer, P. H.

Tumor counterattack--concept and reality 30 (3), Eur J Immunol, 725-31, 2000

Igney, F. H., Behrens, C. K., Krammer, P. H.

CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo 113 (1), Int J Cancer, 78-87, 2005

Igney, F. H., Krammer, P. H.

Immune escape of tumors: apoptosis resistance and tumor counterattack 71 (6), J Leukoc Biol, 907-20, 2002

Igney, F. H., Krammer, P. H.

Death and anti-death: tumour resistance to apoptosis 2 (4), Nat Rev Cancer, 277-88, 2002

Peshes-Yaloz, N., Rosen, D., Sondel, P. M., Krammer, P. H., Berke, G.

Up-regulation of Fas (CD95) expression in tumour cells in vivo 120 (4), Immunology, 502-11, 2007

Schiffenbauer, Y. S., Trubniykov, E., Zacharia, B. T., Gerbat, S., Rehavi, Z., Berke, G., Chaitchik, S.

Tumor sensitivity to anti-cancer drugs predicted by changes in fluorescence intensity and polarization in vitro 22 (5), Anticancer Res, 2663-9, 2002

to top